Biotricity (BTCY) Competitors

Daxor (NASDAQ:DXR) and Biotricity (NASDAQ:BTCY) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, community ranking, media sentiment, earnings, dividends and risk.

Which has more risk & volatility, DXR or BTCY?

Daxor has a beta of -0.46, meaning that its stock price is 146% less volatile than the S&P 500. Comparatively, Biotricity has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500.

Do analysts recommend DXR or BTCY?

Daxor currently has a consensus price target of $24.75, suggesting a potential upside of 241.85%. Given Daxor's stronger consensus rating and higher possible upside, equities research analysts clearly believe Daxor is more favorable than Biotricity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daxor	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Biotricity	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Which has higher valuation & earnings, DXR or BTCY?

Daxor has higher earnings, but lower revenue than Biotricity.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daxor	$2.61M	13.44	N/A	N/A	N/A
Biotricity	$12.06M	1.31	-$14.09M	-$1.08	-0.60

Do insiders and institutionals have more ownership in DXR or BTCY?

1.3% of Daxor shares are owned by institutional investors. Comparatively, 3.9% of Biotricity shares are owned by institutional investors. 59.0% of Daxor shares are owned by company insiders. Comparatively, 10.1% of Biotricity shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Does the MarketBeat Community prefer DXR or BTCY?

Daxor received 1 more outperform votes than Biotricity when rated by MarketBeat users. Likewise, 100.00% of users gave Daxor an outperform vote while only 0.00% of users gave Biotricity an outperform vote.

Company	Underperform	Outperform
Daxor	Outperform Votes 1 100.00%	Underperform Votes No Votes
Biotricity	Outperform Votes No Votes	Underperform Votes 2 100.00%

Is DXR or BTCY more profitable?

Daxor has a net margin of 0.00% compared to Biotricity's net margin of -80.42%.

Company	Net Margins	Return on Equity	Return on Assets
Daxor	N/A	N/A	N/A
Biotricity	-80.42%	N/A	-192.16%

Does the media prefer DXR or BTCY?

In the previous week, Biotricity had 1 more articles in the media than Daxor. MarketBeat recorded 4 mentions for Biotricity and 3 mentions for Daxor. Daxor's average media sentiment score of 0.00 equaled Biotricity'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Daxor	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biotricity	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Daxor beats Biotricity on 9 of the 13 factors compared between the two stocks.